Profound Medical (PROF) Cash from Operations Growth (1y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -84.38% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 185.96% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 16.00% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.60% |
| 10 | Profound Medical | 244.28 Mn | 193.99 Mn | 3.83 Mn | -3.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.62% |
| Dec 31, 2025 | -11.69% |
| Sep 30, 2025 | -40.84% |
| Jun 30, 2025 | -121.00% |
| Mar 31, 2025 | -82.89% |
| Dec 31, 2024 | 19.78% |
| Sep 30, 2024 | -57.35% |
| Jun 30, 2024 | 62.90% |
| Mar 31, 2024 | -177.78% |
| Dec 31, 2023 | 83.71% |
| Sep 30, 2023 | -175.38% |
| Jun 30, 2023 | -178.76% |
| Mar 31, 2023 | 174.09% |
| Dec 31, 2022 | -13.40% |
| Sep 30, 2022 | -80.55% |
| Jun 30, 2022 | 453.76% |
| Mar 31, 2022 | -225.32% |
| Dec 31, 2021 | -92.80% |
| Sep 30, 2021 | 779.98% |
| Jun 30, 2021 | -21.40% |
| Mar 31, 2021 | 215.56% |
| Dec 31, 2020 | -236.70% |
| Sep 30, 2020 | -72.78% |
| Jun 30, 2020 | -5.49% |
| Mar 31, 2020 | -124.26% |
| Dec 31, 2019 | 161.66% |